Tectonic Therapeutic (NASDAQ:TECX) Coverage Initiated at Piper Sandler

Analysts at Piper Sandler began coverage on shares of Tectonic Therapeutic (NASDAQ:TECX) in a note issued to investors on Wednesday, Marketbeat Ratings reports. The brokerage set an “overweight” rating and a $76.00 price target on the stock. Piper Sandler’s price target would indicate a potential upside of 360.89% from the stock’s previous close.

Separately, TD Cowen assumed coverage on shares of Tectonic Therapeutic in a research note on Monday. They set a “buy” rating on the stock.

Tectonic Therapeutic Trading Up 3.5 %

NASDAQ:TECX opened at $16.49 on Wednesday. Tectonic Therapeutic has a twelve month low of $10.56 and a twelve month high of $19.80. The firm has a market cap of $740.24 million, a P/E ratio of 23.90 and a beta of 1.23.

Tectonic Therapeutic (NASDAQ:TECX) last issued its earnings results on Thursday, May 9th. The company reported ($0.15) earnings per share for the quarter.

Tectonic Therapeutic Company Profile

Avrobio, Inc is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc is based in MA, United States.